Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Rises By 206.2%

PicoCELA Inc. (NASDAQ:PCLA) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 113,864 shares, a growth of 206.2% from the June 15th total of 37,187 shares. Based on an average daily volume of 822,239 shares, the days-to-cover ratio is currently 0.1 days. Approximately 284.7% of the company’s shares are short sold.

PicoCELA Stock Performance

Shares of NASDAQ:PCLA traded down $0.38 during mid-day trading on Tuesday, reaching $4.50. 588,534 shares of the company were exchanged, compared to its average volume of 798,129. PicoCELA has a 1 year low of $1.35 and a 1 year high of $112.20. The firm’s 50-day simple moving average is $4.93 and its 200 day simple moving average is $4.68.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. Jane Street Group LLC purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned 18.92% of PicoCELA at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.